 "Cipla, Cipla logo, Cipla headquarters")
Mumbai-based drug maker Cipla posted a 10 per cent year-on-year rise in net profit to Rs 801 crore for the third quarter of the financial year 2022-23, riding on the back of a six per cent surge in total revenue from operations to Rs 5,810 crore.
Cipla posted an Ebitda of Rs 1,408 crore for the quarter with a resulting Ebitda margin of 24.2 percent.
The firm's stock ended 2.12 per cent down, at Rs 1,039 on the BSE.
Kunal Randeria, analyst with Nuvama Research, said the revenue was due to emerging markets and active pharmaceutical ingredients (API) performance, and Covid-19 contribution to
